Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer

Purpose To estimate the risks of ovarian cancer and breast cancer associated with oral contraceptive (OC) use among women at elevated risk owing to mutations in BRCA1/2 or a strong family history. Methods We searched PubMed, Embase, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov for studies published 2000 to 2012 that evaluated associations between OC use and breast or ovarian cancer among women who are carriers of a BRCA1/2 mutation or have a family history of breast or ovarian cancer. Results From 6,476 unique citations, we identified six studies examining ovarian cancer risk in BRCA1/2 mutation carriers and eight studies examining breast cancer risk in BRCA1/2 mutation carriers. For BRCA1/2 mutation carriers combined, meta-analysis showed an inverse association between OC use and ovarian cancer (odds ratio [OR], 0.58; 95% CI, 0.46 to 0.73) and a nonstatistically significant association with breast cancer (OR, 1.21; 95% CI, 0.93 to 1.58). Findings were similar when examining BRCA1 and BRCA2 mutation carriers separately. Data were inadequate to perform meta-analyses examining duration or timing of use. For women with a family history of ovarian or breast cancer, we identified four studies examining risk for ovarian cancer and three for breast cancer, but differences between studies precluded combining the data for meta-analyses, and no overall pattern could be discerned. Conclusion Our analyses suggest that associations between ever use of OCs and ovarian and breast cancer among women who are BRCA1 or BRCA2 mutation carriers are similar to those reported for the general population.

Download Full-text

Family History of Cancer, Oral Contraceptive Use, and Ovarian Cancer Risk

Obstetrical & Gynecological Survey ◽

10.1097/00006254-200205000-00016 ◽

2002 ◽

Vol 57 (5) ◽

pp. 288-290 ◽

Cited By ~ 2

Author(s):

Gail R. Walker ◽

James J. Schlesselman ◽

Roberta B. Ness

Keyword(s):

Ovarian Cancer ◽

Oral Contraceptive ◽

Family History ◽

Cancer Risk ◽

Contraceptive Use ◽

Ovarian Cancer Risk ◽

Family History Of Cancer ◽

Oral Contraceptive Use ◽

History Of ◽

History Of Cancer

Download Full-text

Family History of Reproductive Cancers and Ovarian Cancer Risk: An Italian Case-Control Study

American Journal of Epidemiology ◽

10.1093/oxfordjournals.aje.a116199 ◽

1992 ◽

Vol 135 (1) ◽

pp. 35-40 ◽

Cited By ~ 45

Author(s):

Fabio Parazzini ◽

Eva Negri ◽

Carlo La Vecchia ◽

Carlo Restelli ◽

Silvia Franceschi

Keyword(s):

Ovarian Cancer ◽

Family History ◽

Cancer Risk ◽

Case Control Study ◽

Case Control ◽

Ovarian Cancer Risk ◽

Italian Case ◽

History Of ◽

Reproductive Cancers ◽

Control Study

Download Full-text

Internet use is associated with utilization of genetic counseling for BRCA 1/2 mutations in women with a family history of breast or ovarian cancer

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.10654 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 10654-10654 ◽

Cited By ~ 1

Author(s):

K. Armstrong ◽

S. Gray ◽

S. Domchek

Keyword(s):

Ovarian Cancer ◽

Genetic Counseling ◽

Family History ◽

Cancer Risk ◽

Health Information ◽

Internet Use ◽

The Internet ◽

Frequent Use ◽

Brca 1 ◽

History Of

10654 Background: Women obtain breast cancer risk information from a variety of sources including mass media, the internet and personal and professional sources. Little is know about how internet use for health information influences choices about breast cancer risk evaluation and decision making. Methods: Case control study of 408 women with a family history of breast or ovarian cancer, of whom 217 underwent genetic counseling for BRCA 1/2 testing (cases) and 191 women who did not (controls). Participants received primary care within a large health system in greater Philadelphia, PA. Results: Women with a family history of breast or ovarian cancer who reported frequent use of the internet for health information (>1–2 times a month) were significantly more likely to undergo genetic counseling for BRCA 1/2 testing than women that rarely used the internet to obtain health information (<2 times a year) (odds ratio 2.6; 95% CI 1.7–4.0). This association persisted after adjustment for age, race, education and Gail risk (adjusted odds ratio 2.1; 95% CI 1.05–4.2) Conclusions: Frequent use of the internet for health care information is associated with higher use of genetic counseling for BRCA 1/2 mutations in women with a family history of breast or ovarian cancer. The association can not be explained by differences in education, cancer risk, age or race. A possible hypothesis for this association is that internet use exposes women to more information about genetic testing, BRCA testing opportunities and the experiences of other women who have utilized BRCA counseling services. No significant financial relationships to disclose.

Download Full-text

A prospective study of reproductive factors and exogenous hormone use in relation to ovarian cancer risk among Black women

Cancer Causes & Control ◽

10.1007/s10552-016-0840-4 ◽

2016 ◽

Vol 28 (5) ◽

pp. 385-391 ◽

Cited By ~ 4

Author(s):

Traci N. Bethea ◽

Julie R. Palmer ◽

Lucile L. Adams-Campbell ◽

Lynn Rosenberg

Keyword(s):

Ovarian Cancer ◽

Black Women ◽

Cancer Risk ◽

Prospective Study ◽

Reproductive Factors ◽

Ovarian Cancer Risk ◽

Exogenous Hormone ◽

Hormone Use ◽

A Prospective Study

Download Full-text

The genetic analysis of a founder Northern American population of European descent identifies FANCI as a candidate familial ovarian cancer risk gene

10.1101/2020.05.04.20090407 ◽

2020 ◽

Cited By ~ 1

Author(s):

Caitlin T Fierheller ◽

Laure Guitton-Sert ◽

Wejdan M Alenezi ◽

Timothée Revil ◽

Kathleen K Oros ◽

...

Keyword(s):

Ovarian Cancer ◽

Dna Repair ◽

Family History ◽

Serous Carcinoma ◽

Ovarian Cancer Risk ◽

Repair Pathway ◽

Degree Relative ◽

Pathogenic Variants ◽

Familial Ovarian Cancer ◽

History Of

AbstractSome familial ovarian cancer (OC) could be due to rare risk alleles in genes that each account for a relatively small proportion of cases not due to BRCA1 and BRCA2, major risk genes in the homologous recombination (HR) DNA repair pathway. We report a new candidate OC risk allele, FANCI c.1813C>T in a Fanconi anemia (FA) gene that plays a role upstream of the HR DNA repair pathway. This variant was identified by whole exome sequencing of a BRCA1 and BRCA2 mutation-negative French Canadian (FC) OC family from a population exhibiting founder effects. In FCs, the c.1813C>T allele was detected in 7% (3/43) of familial and 1.6% (7/439) of sporadic OC cases; and in 3.7% (3/82) of familial breast cancer (BC) cases with a family history of OC and in 1.9% (3/158) of BC only families. This allele was significantly associated with FC BRCA1 and BRCA2 mutation-negative OC families (OR=5.6; 95%CI=1.6-19; p=0.006). Although FANCI c.1813C>T was detected in 2.5% (74/2950) of cancer-free FC females, carriers had a personal history of known OC risk reducing factors, and female/male carriers were more likely to have reported a first-degree relative with OC (ρ=0.037; p=0.011). Eight rare potentially pathogenic FANCI variants were identified in 3.3% (17/516) of Australian OC cases, including 10 carriers of FANCI c.1813C>T. Potentially pathogenic FANCI variants were significantly more common in AUS OC cases with a family history of OC than in isolated OC cases (p=0.027). The odds ratios (OR) were >3 for carriers of any of the seven rarest FANCI alleles, and 1.5 for c.1813C>T. Data from the OC Association Consortium revealed that the ORs for the c.1813C>T allele were highest for the most common OC subtypes. Localization of FANCD2, part of the FANCI-FANCD2 (ID2) binding complex in the FA pathway, to sites of induced DNA damage was severely impeded in cells expressing the p.L605F isoform. This isoform was expressed at a reduced level; unstable by formaldehyde or mitomycin C treatment; and exhibited sensitivity to cisplatin but not to olaparib (a poly [ADP-ribose] polymerase inhibitor). By tissue microarray analyses, FANCI protein was robustly expressed in fallopian tube epithelial cells but expressed at low-to-moderate levels in 88% (83/94) of high-grade serous carcinoma OC samples. This is the first study to describe potentially pathogenic variants in OC in a member of the ID2 complex of the FA DNA repair pathway. Our data suggest that potentially pathogenic FANCI variants may modify OC risk in cancer families.

Download Full-text